Welcome to our dedicated page for Microbot Med SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. filed a Form D reporting a completed Regulation D private offering under Rule 506(b). The issuer raised aggregate proceeds of $25,244,903, of which $25,244,903 has been sold and $0 remains. The filing states the total offering amount reflects the aggregate exercise price of inducement preferred investment options and placement-agent preferred investment options. The placement agent received cash fees totaling $2,095,542 and was also granted 1,342,694 preferred investment options exercisable for common stock at prices ranging from $1.875 to $2.6625. The offering was a new notice with a first sale date of 2025-09-16, claimed a minimum investment of $0, and was not part of a business combination. The Form D was signed by CFO Rachel Vaknin on 2025-09-29.
Microbot Medical Inc. filed a current report to share that its Chief Executive Officer, Harel Gadot, will appear on Benzinga All Access at 10:45 a.m. ET on Wednesday, September 24, 2025. During the interview, he is expected to discuss the recent FDA clearance of the Company’s LIBERTY® system and how the Company has planned for its commercialization in the United States.
The Company furnished a related press release as Exhibit 99.1, and this communication is being treated as “furnished” rather than “filed” under securities laws. The filing highlights ongoing communication with the market about Microbot Medical’s efforts to redefine the peripheral endovascular space with its LIBERTY® technology.
Microbot Medical Inc. filed a current report to share that its Chief Executive Officer, Harel Gadot, will appear on Benzinga All Access at 10:45 a.m. ET on Wednesday, September 24, 2025. During the interview, he is expected to discuss the recent FDA clearance of the Company’s LIBERTY® system and how the Company has planned for its commercialization in the United States.
The Company furnished a related press release as Exhibit 99.1, and this communication is being treated as “furnished” rather than “filed” under securities laws. The filing highlights ongoing communication with the market about Microbot Medical’s efforts to redefine the peripheral endovascular space with its LIBERTY® technology.
Microbot Medical Inc. disclosed that its board’s Compensation Committee approved special one-time cash bonuses for several executives and non‑management directors. CEO, President and Chairman Harel Gadot received $158,115, CTO Simon Sharon received approximately $64,200, and executive officer Rachel Vaknin received approximately $32,500. The committee also authorized one-time cash payments of $30,000 to $45,000 for each non‑management board member.
The committee noted that these payments reflect, in part, that the executives had previously waived 30–50% of their prorated 2023 base salaries under the company’s May 2023 cost restructuring plan.
Microbot Medical Inc. disclosed that its board’s Compensation Committee approved special one-time cash bonuses for several executives and non‑management directors. CEO, President and Chairman Harel Gadot received $158,115, CTO Simon Sharon received approximately $64,200, and executive officer Rachel Vaknin received approximately $32,500. The committee also authorized one-time cash payments of $30,000 to $45,000 for each non‑management board member.
The committee noted that these payments reflect, in part, that the executives had previously waived 30–50% of their prorated 2023 base salaries under the company’s May 2023 cost restructuring plan.
Microbot Medical Inc. entered into an inducement agreement with certain holders of its existing preferred investment options, who agreed to exercise options to buy up to 13,989,115 shares of common stock for cash in exchange for new Series J preferred investment options to buy up to 13,989,115 shares at an exercise price of $4.50 per share. At a first closing, holders exercised options for up to 12,064,627 shares, generating approximately $25.2 million in gross proceeds, and a second closing is expected to add exercises for up to 1,924,488 shares for approximately $4.0 million in gross proceeds.
The company plans to use the net proceeds to advance development, commercialization and regulatory activities for its LIBERTY® Robotic System, pursue potential acquisitions, expand applications from its IP portfolio, and for working capital and general corporate purposes. Microbot also issued unregistered new options to investors and to H.C. Wainwright & Co., which served as exclusive placement agent and will receive cash fees, expense reimbursements, and additional preferred investment options tied to current and future cash exercises.
Microbot Medical Inc. furnished an update under Regulation FD by making new investor presentation materials available on its website. The slides can be accessed through the ‘Investors’ section under ‘IR Resources’ and then ‘Additional Resources.’
The company also highlighted its participation in the H.C. Wainwright Annual Investor Conference in New York, where President, CEO and Chairman Harel Gadot is scheduled to present on September 9, 2025, with a live webcast available through the ‘Events’ section of the website. The presentation materials are furnished as Exhibit 99.1 to this report and are expressly described as furnished, not filed, which limits their treatment under certain securities law liability provisions.
Microbot Medical Inc. filed an 8-K to report that the U.S. Food and Drug Administration has granted 510(k) clearance for its LIBERTY® Endovascular Robotic System, described as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. This clearance allows the company to move ahead with final commercial activities that depended on marketing clearance and to begin U.S. commercialization, with an aim to address approximately 2.5 million annual U.S. peripheral vascular procedures and later pursue global markets. The company also disclosed that its President, CEO and Chairman, Harel Gadot, is presenting at the H.C. Wainwright Annual Investor Conference in New York on September 9, 2025, with a live webcast available via its website.
Microbot Medical Inc. reported that from August 26 to August 27, 2025 it issued 4,055,870 new shares of common stock through the exercise of previously issued preferred investment options. Holders exercised 300,000 Series H options at $2.10 per share and 3,755,870 Series I options at $2.13 per share, providing the company with approximately $8.6 million in gross cash proceeds before fees and expenses. As of August 27, 2025, Microbot Medical had about 52,569,762 common shares outstanding. The company relied on a private offering exemption under Section 4(a)(2), while the shares underlying both the Series H and Series I options had already been registered for resale on prior Form S-3 registration statements.
Microbot Medical Inc. reported unregistered sales of its common stock tied to option exercises. From August 11 to August 25, 2025, the company issued an aggregate of 2,967,953 shares of common stock upon the exercise of outstanding Series E, Series G, and Series H preferred investment options at exercise prices of $1.50, $1.75, and $2.10 per share, respectively, generating approximately $5.9 million in gross proceeds before fees and expenses. Microbot also issued 47,218 shares of common stock upon the exercise of incentive options by a former director. As of August 25, 2025, the company had approximately 48,513,892 shares of common stock issued and outstanding. The shares were issued as private transactions under Section 4(a)(2) of the Securities Act, and the shares underlying the preferred investment options had been previously registered for resale on Form S-3 registration statements.
Microbot Medical Inc. reported that the U.S. Patent and Trademark Office has granted it a patent covering a modular robotic surgical system with a base and multiple independently attachable tool-receiver units. The company explains that this patent may allow its LIBERTY device to be adapted over time for a wider range of endovascular procedures, which could substantially increase the total addressable market it seeks to reach. The patent also broadens Microbot’s intellectual property protection for the LIBERTY system portfolio, which now consists of 12 patents granted globally and 57 patent applications pending.
Microbot Medical Inc. discloses that three reporting persons — Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC — may be deemed to beneficially own 4,200,951 shares of common stock, representing 9.99% of the class. That total consists of 7,700 shares held directly by Intracoastal and two warrants exercisable into 2,349,488 and 1,843,763 shares, respectively, which together create the reported position and corresponding shared voting and dispositive power.
The filing also discloses several warrant blocker provisions that exclude additional potential shares from the reported total: certain warrants cannot be exercised to the extent they would push ownership above 9.99% or 4.99%. The filing states that without those blocker provisions the reporting persons could be deemed to beneficially own 7,695,600 shares. The signatories certify the holdings were not acquired to change or influence control of the issuer.